Literature DB >> 22233583

Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells.

Jeffrey M Zirger1, Mariana Puntel, Josee Bergeron, Mia Wibowo, Rameen Moridzadeh, Niyati Bondale, Carlos Barcia, Kurt M Kroeger, Chunyan Liu, Maria G Castro, Pedro R Lowenstein.   

Abstract

The adaptive immune response to viral vectors reduces vector-mediated transgene expression from the brain. It is unknown, however, whether this loss is caused by functional downregulation of transgene expression or death of transduced cells. Herein, we demonstrate that during the elimination of transgene expression, the brain becomes infiltrated with CD4(+) and CD8(+) T cells and that these T cells are necessary for transgene elimination. Further, the loss of transgene-expressing brain cells fails to occur in the absence of IFNγ, perforin, and TNFα receptor. Two methods to induce severe immune suppression in immunized animals also fail to restitute transgene expression, demonstrating the irreversibility of this process. The need for cytotoxic molecules and the irreversibility of the reduction in transgene expression suggested to us that elimination of transduced cells is responsible for the loss of transgene expression. A new experimental paradigm that discriminates between downregulation of transgene expression and the elimination of transduced cells demonstrates that transduced cells are lost from the brain upon the induction of a specific antiviral immune response. We conclude that the anti-adenoviral immune response reduces transgene expression in the brain through loss of transduced cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233583      PMCID: PMC3321600          DOI: 10.1038/mt.2011.243

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  46 in total

Review 1.  Oncolytic adenoviruses as antiglioma agents.

Authors:  Hong Jiang; Frank McCormick; Frederick F Lang; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  Expert Rev Anticancer Ther       Date:  2006-05       Impact factor: 4.512

2.  Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells.

Authors:  B P Zambrowicz; A Imamoto; S Fiering; L A Herzenberg; W G Kerr; P Soriano
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase.

Authors:  Y Kanegae; G Lee; Y Sato; M Tanaka; M Nakai; T Sakaki; S Sugano; I Saito
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

4.  Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

Authors:  Haiyan Jiang; Linda B Couto; Susannah Patarroyo-White; Tongyao Liu; Dea Nagy; Joseph A Vargas; Shangzhen Zhou; Ciaran D Scallan; Jurg Sommer; Sharmila Vijay; Federico Mingozzi; Katherine A High; Glenn F Pierce
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

5.  Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo.

Authors:  J Yang; N S R Sanderson; K Wawrowsky; M Puntel; M G Castro; P R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

6.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

7.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

Authors:  Frederick F Lang; Janet M Bruner; Gregory N Fuller; Kenneth Aldape; Michael D Prados; Susan Chang; Mitchel S Berger; Michael W McDermott; Sandeep M Kunwar; Larry R Junck; William Chandler; James A Zwiebel; Richard S Kaplan; W K Alfred Yung
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

8.  In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain.

Authors:  Carlos Barcia; Clare E Thomas; James F Curtin; Gwendalyn D King; Kolja Wawrowsky; Marianela Candolfi; Wei-Dong Xiong; Chunyan Liu; Kurt Kroeger; Olivier Boyer; Jerzy Kupiec-Weglinski; David Klatzmann; Maria G Castro; Pedro R Lowenstein
Journal:  J Exp Med       Date:  2006-08-21       Impact factor: 14.307

Review 9.  The host immunologic response to West Nile encephalitis virus.

Authors:  Michael S Diamond; Erin Mehlhop; Theodore Oliphant; Melanie A Samuel
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo.

Authors:  G F Rall; L Mucke; M B Oldstone
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

2.  Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.

Authors:  L Samaranch; P Hadaczek; A P Kells; J R Bringas; D Stockinger; W San Sebastian; M Macayan; S Samineni; P Pivirotto; J Forsayeth; K S Bankiewicz
Journal:  Gene Ther       Date:  2015-08-23       Impact factor: 5.250

Review 3.  Kupfer-type immunological synapses in vivo: Raison D'être of SMAC.

Authors:  Izaskun Mitxitorena; Elena Saavedra; Carlos Barcia
Journal:  Immunol Cell Biol       Date:  2014-09-30       Impact factor: 5.126

4.  Phosphatidylserine Exposure Controls Viral Innate Immune Responses by Microglia.

Authors:  Yusuf Tufail; Daniela Cook; Lawrence Fourgeaud; Colin J Powers; Katharina Merten; Charles L Clark; Elizabeth Hoffman; Alexander Ngo; Kohei J Sekiguchi; Clodagh C O'Shea; Greg Lemke; Axel Nimmerjahn
Journal:  Neuron       Date:  2017-01-19       Impact factor: 17.173

Review 5.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

Review 6.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

7.  Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Authors:  Gregory J Baker; Peter Chockley; Viveka Nand Yadav; Robert Doherty; Michael Ritt; Sivaraj Sivaramakrishnan; Maria G Castro; Pedro R Lowenstein
Journal:  Cancer Res       Date:  2014-07-18       Impact factor: 12.701

Review 8.  The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.

Authors:  P R Lowenstein; M G Castro
Journal:  Adv Pharmacol       Date:  2016-04-23

Review 9.  Consensus guidelines for the detection of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

10.  A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1.

Authors:  Diana Shah; Andrea Comba; Syed M Faisal; Padma Kadiyala; Gregory J Baker; Mahmoud S Alghamri; Robert Doherty; Daniel Zamler; Gabriel Nuñez; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2021-06-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.